Universiteit Maastricht
Universiteit Maastricht is recorded as a service provider in 1 clinical trial. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 1 of 1 trials · Latest update first
A Phase 2, multicenter, open-label, nonrandomized, proof-of-concept study evaluating the efficacy, safety, and tolerability of SAR445088 in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
Operational learnings available5 trial-level findings · Read insights
- The study enrolled 98 of 140 screened participants from 28 April 2021 to 30 January 2024 at 28 centres in 10 countries; 42 participants were screen failures.
- Eligibility criteria for hepatitis B were clarified in an October 2021 substantial protocol amendment.
- A low-dose SoC-refractory cohort and Part C long-term extension were added in June 2022, and enrollment in the low-dose SoC-refractory cohort was increased in December 2022 to support a more robust dose evaluation.
- A low-dose SoC-treated cohort was added in June 2023 to collect additional data.
- In January 2024, participants initially assigned to weekly initial-dose riliprubart were changed to weekly low-dose riliprubart; the dose reduction was not safety driven.
These findings describe the trial, not the service provider’s performance or responsibility.
Questions about this trial experience
What services are recorded for Universiteit Maastricht?
The 2026-10-09 snapshot links Universiteit Maastricht to 1 distinct CTIS trials. Recorded services include Medical expertise. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Universiteit Maastricht?
The most frequently recorded therapeutic areas are Immunology, Neurology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Universiteit Maastricht conducted?
The linked trials record locations in 6 countries, including Germany, Spain, France, Italy, Netherlands. These are trial locations, not confirmed office locations or countries where Universiteit Maastricht delivered services.
What can this page tell me about Universiteit Maastricht's trial experience?
Browse 1 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Universiteit Maastricht. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Universiteit Maastricht